Doctors tested a chemical called PEG during nerve repair surgery on badly injured arm nerves. Patients who got PEG recovered feeling and movement much faster than those who had standard repair alone.
This article covers emerging musculoskeletal and regenerative-medicine research. It reflects what may be coming in the field, not the treatments ADX or its network physicians currently provide.
Why it matters
When a nerve in the arm is completely cut, it usually has to grow back on its own, and that happens slowly, only about a millimeter a day. While patients wait, the hand can stay numb and muscles can weaken. A chemical called PEG, used during nerve repair surgery, may let doctors reconnect the cut nerve ends right away, so some feeling and movement come back in weeks instead of months.
Summary
A pilot double-blind randomized clinical trial published in the Journal of the American College of Surgeons (Gutama et al., May 2026) tested whether adding polyethylene glycol (PEG) to standard nerve repair surgery speeds recovery after severe traumatic nerve injuries. The multi-institution research group enrolled 13 adults with complete (Sunderland grade V) injuries to the median or ulnar nerve in the forearm, the two nerves that carry most of the feeling and fine motor control to the hand, producing 17 individual nerve repairs.
Patients were randomly assigned, with neither patients nor evaluators told which treatment they had received, to standard microsurgical nerve repair (suturing the cut ends back together) or the same repair plus a brief application of a PEG solution at the repair site during surgery. PEG is thought to work by fusing the outer membranes of severed axons back together at the time of surgery, potentially restoring some signal conduction across the injury site right away rather than waiting for the nerve fibers to regrow. Researchers tracked recovery using the Medical Research Council Classification (MRCC) for sensory and motor grading and the Michigan Hand Questionnaire (MHQ), a patient-reported measure of hand function, over more than 13 months of follow-up.
By 22 days after surgery, patients who received PEG had reached sensory grades of S3 or better and motor grades of M3 or better, while patients who had standard repair alone remained at S2/M2 or lower at that point, a gap the authors report was largely sustained across later visits. The PEG group also reported significantly lower postoperative pain and scored higher on the Michigan Hand Questionnaire. The trial is small – 13 patients (8 assigned to PEG, 5 to standard repair), contributing 10 PEG-treated nerve repairs versus 7 standard repairs – and the authors describe it as a pilot study meant to test feasibility and estimate an effect size for a larger trial, not to prove the technique works in general use. It is among the first controlled human comparisons of PEG-assisted repair for major upper-extremity nerve injuries, and a companion invited commentary in the same journal issue reflects active surgeon interest in the approach. If the early-recovery advantage holds up in larger trials, PEG-assisted repair could eventually let patients with severe nerve injuries regain hand sensation and function measurably sooner than they do today.
Source: Gutama et al., Role of Polyethylene Glycol-Mediated Axonal Fusion in Early Recovery of Median and Ulnar Nerve Injury: A Pilot Double-Blind Randomized Clinical Trial. Journal of the American College of Surgeons, 2026. PubMed. Full text: doi:10.1097/xcs.0000000000001795.
Research compiled by ADX AI Agent, reviewed by Sean Gallivan